Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: COCP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.84% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.54M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 2.28 | 52 Weeks Range 1.12 - 3.26 | Updated Date 09/17/2025 |
52 Weeks Range 1.12 - 3.26 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.87% | Return on Equity (TTM) -110.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10433703 | Price to Sales(TTM) 92.45 |
Enterprise Value 10433703 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 10258900 | Shares Floating 6639846 |
Shares Outstanding 10258900 | Shares Floating 6639846 | ||
Percent Insiders 36.05 | Percent Institutions 6.69 |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma, Inc. was founded in 2007. It focuses on developing new antiviral therapeutics targeting influenza viruses, noroviruses, coronaviruses, and hepatitis C viruses. The company has primarily focused on discovering and developing new antiviral compounds.
Core Business Areas
- Antiviral Drug Development: Cocrystal Pharma focuses on discovering and developing antiviral drugs to treat and prevent infectious diseases. They utilize their cocrystal technology to create new and improved antiviral therapies.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is focused on research and development, clinical trials, and commercialization of antiviral drugs.
Top Products and Market Share
Key Offerings
- CC-42344 (Influenza A Inhibitor): CC-42344 is Cocrystal Pharma's influenza A inhibitor. It is currently undergoing clinical development. Market share data is not publicly available as it's not yet commercialized. Competitors include Roche (Tamiflu), and BioCryst Pharmaceuticals (Rapivab).
- CC-223 (Pan-Coronavirus Inhibitor): CC-223 is being developed as a pan-coronavirus protease inhibitor. It is currently in pre-clinical development. It's too early to determine market share or competition.
Market Dynamics
Industry Overview
The antiviral drug market is driven by the increasing prevalence of infectious diseases, growing awareness of antiviral therapies, and advancements in drug development technologies.
Positioning
Cocrystal Pharma is positioned as a research-focused company developing novel antiviral therapeutics using its cocrystal technology. Its competitive advantage lies in its innovative approach to drug discovery.
Total Addressable Market (TAM)
The global antiviral drug market is estimated at several billion dollars annually. Cocrystal Pharma is positioned to capture a share of this market with successful development and commercialization of its antiviral drugs. Exact TAM varies greatly based on drug and indication. For example, the influenza market is distinct from the norovirus market.
Upturn SWOT Analysis
Strengths
- Novel cocrystal technology platform
- Experienced management team
- Focus on unmet medical needs in antiviral therapy
- Promising pipeline of antiviral drug candidates
Weaknesses
- Limited financial resources
- Dependence on external funding
- Early-stage pipeline development
- Lack of established commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Out-licensing of drug candidates
- Expansion of pipeline to address other viral diseases
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Intellectual property challenges
- Changing market dynamics and pricing pressures
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- BioCryst Pharmaceuticals (BCRX)
- Gilead Sciences (GILD)
Competitive Landscape
Cocrystal Pharma faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its novel technology and focus on specific viral targets. However, it's disadvantaged by its limited resources and early-stage pipeline.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in the company's pipeline and successful fundraising. The company has not yet achieved commercial success.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its antiviral drugs. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its influenza A inhibitor (CC-42344) through clinical trials and developing new antiviral compounds targeting coronaviruses.
Summary
Cocrystal Pharma is a research-stage biotech company with a novel cocrystal technology platform targeting antiviral therapies. The company's future depends on the success of its clinical trials and its ability to secure partnerships or funding. The company's lack of revenue and dependence on external funding are significant risks. Its success relies on its R&D and positive clinical data.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Market Research Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cocrystalpharma.com |
Full time employees 11 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.